Objective: To examine the frequency and predictors of good outcome for patients with first-episode schizophrenia spectrum disorder (SSD).
T he course of schizophrenia, and schizophrenia-like disorders, shows large individual differences; therefore, identification of possible predictors of course and outcome is very important. As the disorder appears to be heterogeneous, 1 detection of significant early clinical features is critical if developing a treatment to alter the long-term course of the illness is possible. DUP, 2-6 male sex, age at onset, 7, 8 severe psychopathology, [9] [10] [11] premorbid functioning, 2, 12, 13 adherence to medication, 14 and substance abuse [15] [16] [17] were often found to have significant predictive value in studies of first-episode schizophrenia and schizophrenia-like psychosis.
We aimed to investigate the frequency of good outcomes at a 2-year follow-up of patients with first-episode SSD and to identify predictors of these outcomes.
We hypothesized that older age at entry, female sex, good premorbid functioning, short DUP, long education, no substance abuse at entry, few severe symptoms at entry, adherence to medication, and an intensive early intervention program (that is, OPUS) would predict good outcome after 2 years. Etiological factors, for example, genetic factors, pregnancy and delivery complications, brain abnormalities, cognitive functioning, and rearing atmosphere, are all known to influence the course of the illness; however, they are not investigated in this study and therefore are not included in our hypotheses.
Method

Participants and Design
A cohort of patients (n = 547) from Copenhagen and Aarhus with first-episode SSD were included in the OPUS trial and followed for 2 years. The Danish OPUS trial is a randomized controlled trial comparing OPUS treatment (comprising intensive psychosocial assertive community treatment, psychoeducation, social skills training, family treatment, and multifamily groups) with standard treatment (standard mental health service routines, with contacts primarily in the community mental health centre, higher caseloads, and only a minor proportion of patients offered supportive contacts.) In both groups, medication followed the guidelines of The Danish Psychiatric Association, primarily using the newer antipsychotic medication in a low dosage. The intervention program and the results of the trial are reported in detail elsewhere. 18 First episode was defined as the first time the patient was treated for a psychotic disorder within the schizophrenia spectrum.
Patients were included in the study if they: were aged from 18 to 45 years; had a diagnosis of schizophrenia, schizotypal disorder, delusional disorder, acute or transient psychosis, schizoaffective disorder, or nonspecific nonorganic psychosis according to the ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 19 ; had not received continuous antipsychotic medication for more than 12 weeks; and the condition was not caused by acute poisoning or a substance withdrawal state.
Patients were referred to the study from all in-and outpatient mental health services in Copenhagen and Aarhus County. The catchment area covered a population of 1 040 000. Patients were included in the study from January 1, 1998, to December 31, 2000. Approval by the Danish Ethics Committee and by the Danish data authorities was obtained before the trial was initiated. All patients gave written informed consent.
Measures
At entry, all patients were comprehensively assessed with SCAN, version 2.0 and 2.1. 20 Substance abuse as secondary diagnosis was measured using SCAN, chapters 11 and 12. Symptoms were assessed with SAPS 21, 22 and SANS. 23 Functioning was assessed with GAF. 24, 25 GAF scales for symptoms and function rate the severity of symptoms and disability with scores from one (most severe) to 100 (no symptoms). SCAN, SANS, and SAPS were completed with reference to the previous month and GAF to the previous week.
DUP was defined as the time between the appearance of at least one psychotic symptom until initiation of adequate treatment. The onset and temporal course of psychotic symptoms were determined with a modified version of Interview for Retrospective Assessment of Onset of Schizophrenia. 26 The duration of each symptom was counted in intervals of months, and the criteria for rating a symptom as present was a retrospective rating of at least one on the Present State Evaluation Rating Scale II (symptom definitely occurring during the period but probably uncommon or transitory), excluding any symptom-free periods of at least one month.
Premorbid functioning was assessed with PAS. 27 PAS subdivides premorbid life into childhood (aged 11 years and younger), early adolescence (aged 12 to 15 years), late adolescence (aged 16 to 18 years), and adulthood (aged 19 years and older). The premorbid period ends, by definition, 6 months before the first psychiatric contact or evidence of florid psychotic symptomatology. For each life period (subscale), there are items covering sociability and withdrawal, peer relations, scholastic performance, adaptation to school (the latter 2 items are not relevant in adulthood), and sociosexual aspects (not relevant in childhood). According to recommendations, we used the split version of the scale. 28 Adulthood scores are not reported because many patients had onset of psychosis before the age of 19 years. Several reports of factor analyses confirm that the PAS covers 2 discrete areas: academic functioning (scholastic performance and adaptation to school) and social functioning (sociability and withdrawal, peer relations, and sociosexual aspects). 29 An overall score (high scores indicate bad functioning) for each of the 2 dimensions of PAS was calculated by averaging the subscale indices for all subscales completed until 6 months prior to the onset of psychosis.
The global measure of medication compliance was based on structured interviews with the patient, the primary case manager, the psychiatrist, and any relevant information in the patients' case notes and prescription cards. Information about medication 3 months prior to the follow-up interview was used in the statistical analyses.
Adherence to medication was dichotomized using the following categories: · Medication was prescribed and started-patients were considered adherent.
· Medication was prescribed but was either not started, or discontinued, or not taken regularly-patients were considered nonadherent.
· Patients with at least mild or more severe global psychotic symptoms who were not prescribed medication and could not be motivated to take medication were categorized as having poor medication compliance and considered nonadherent in the statistical analyses.
· Standard sociodemographic information (for example, school, education, accommodation, and employment status) was also collected.
Criteria for Good Outcome
We used a set of operational criteria for good outcomes, including symptomatic as well as social and (or) vocational dimensions as derived from the proposals of Andreasen et al. 30 Good outcome was defined as: · Psychopathology: all global scores on SAPS (delusions, hallucinations, formal thought disorder, and bizarre behaviour) and SANS (affective flattening, avolition-apathy, anhedonia-asociality, and alogia) rated less than 2 (scores of mild or less). · Social and (or) vocational outcomes: employed or studying, and living independently. If the patient was aged younger than 25 years and living with parents this was also considered as living independently.
· In the domain of hospitalization: not hospitalized during the second year of follow-up.
· Symptomatic remission required a rating of no worse than mild on any global scores of SAPS and SANS. This was a single time point evaluation covering the previous month.
· Being socially and (or) vocationally recovered required that the patients were employed or studying and living independently.
· Full recovery required that the patients fulfilled criteria for both symptom remission and social and (or) vocational recovery, and that they had not been hospitalized during the preceding year.
Outcome Data
Outcome data were collected using the same instruments as at baseline, supplemented with register information about hospital admissions (use of bed days). Independent assessors (psychiatrists, psychologists, and doctors in training as psychiatrists) conducted the follow-up interviews. They were not kept blind to treatment allocation or to the predictor variables as these were part of the baseline data gathered. However, DUP and PAS scores were calculated by complex computerized algorithms after the 2-year follow-up of the cohort was completed.
SAPS and SANS interrater reliability interviews were conducted by the researchers involved in the trial. Agreement was moderate for the negative dimension (the intraclass correlation coefficient was 0.54) and very good for the psychotic dimension (the intraclass correlation coefficient was 0.88). All investigators were SCAN-certified by a World Health Organization collaboration centre.
Data Analysis
Categorical data were analyzed using Pearson's productmoment correlation analysis and the chi-square test. For normally distributed continuous variables, the Student t test was used to evaluate mean differences in the dropout analyses. Bivariate relations among the predictor variables were analyzed with Pearson's coefficient, r, and the chi-square test. Logistic regression analyses with the Wald test were used to analyze the predictors of outcome and to calculate ORs and CIs. The bivariate associations of each outcome variable with each explanatory variable were tested. All variables tested in univariate analyses were simultaneously analyzed in a multivariate model to determine the most potent predictors of good outcome. DUP had a skewed distribution and was transformed using the natural logarithm. All tests of significance were 2-tailed. All tests of prediction of outcome were run separately for patients with schizophrenia with fundamentally the same results. We used SPSS statistical software, version 11.0 (SSPS Inc, Chicago, IL).
Predictors of Outcome
Baseline variables that were found to demonstrate reasonable prognostic value in other studies of outcome in first-episode SSD were included in the analyses: sex; age; treatment site (Copenhagen, compared with Aarhus); natural logarithm of DUP, PAS academic dimension, and PAS social dimension; substance abuse (present, compared with past); psychotic dimension scores; negative dimension scores; vocational education level; adherence to medication; treatment condition (OPUS, compared with standard treatment); and baseline interviews with key relatives.
All predictor variables correlated less than 0.50 (data not shown). Therefore, colinearity was not considered a problem and all variables were included in the logistic regression analyses.
Dropout Analyses
Dropout analyses of the 2-year follow-up interview ( Table 1) showed that significantly more nonparticipants, compared with participants, had substance abuse problems (32.6%, compared with 23.8%, P = 0.03), came from Copenhagen (62.4%, compared with 46.1%, P < 0.001), and had worse scores on PAS academic (mean 0.45, compared with 0.40, P = 0.003). In addition, significantly more nonparticipants, compared with participants, had less than 11 years of schooling at entry (34.1%, compared with 21.2%, P = 0.005) and had no interview with key relatives at entry (53.9%, compared with 34.4%, P = 0.004). Thus the patient group analyzed may represent a positively selected subgroup.
Results
Patient Characteristics
A total of 369 patients (67.5%) participated in the 2-year follow-up interview, of whom 176 were lost to follow-up, 7 died (5 patients committed suicide, one death was unexplained, and one died by accident), one patient withdrew consent, and the remaining 162 could either not be traced, declined to be interviewed, or did not turn up in spite of several letters and home visits. A total of 70% had a diagnosis of schizophrenia, 13% schizotypal disorder, 2% delusional disorder, 6% brief psychosis, 7% schizoaffective disorder, 1% unspecified nonorganic psychosis, and 1% affective disorder. Clinical characteristics, demographic variables, service use, and good outcomes for the trial samples are presented in Table 2 . Table 3 shows that the different outcome variables were associated. Thus between 47% and 94% of the patients had good outcome on 2 or more variables. In addition, all outcome variables showed low-to-moderate positive Pearson's correlations, ranging from 0.05 (from psychotic symptoms to living independently) to 0.46 (from negative symptoms to working and studying). These results demonstrate that outcome in this sample of first-episode SSD consists of semiindependent dimensions as described by Strauss and Carpenter. 31, 32 
Association of Outcome Variables
Predictors of Remission and Recovery
Univariate Analyses. Multivariate Analyses. When all predictors were considered simultaneously in logistic regression analyses, some of the significant univariate predictors became insignificant, which is an indication of the complex interdependence of the predictor variables ( Table 5) . Baseline values of the outcome scales were omitted because we were not primarily interested in predictors of changes from baseline to follow-up but in predictors of the conditions at the time of follow-up.
Fully recovered was best predicted in the multivariate analysis by fewer negative symptoms (OR 0.59; 95%CI, 0.41 to 0.85) and adherence to medication (OR 3.06; 95%CI, 1.15 to 8.12) at baseline. Regarding psychotic symptom outcome, short DUP remained a significant predictor of no symptoms after 2 years (OR 0.83; 95%CI, 0.69 to 0.99). This means that each time DUP is multiplied with e (2.718), OR for remission is reduced by a factor of 0.83. Thus, compared with a DUP of 1 week, a DUP of 2.718 weeks will be associated with a reduced chance of remission (OR 0.83). For a DUP of 55 weeks (2.718), 4 OR for remission is reduced to 0.47 (0.83). 4 Concerning negative symptoms, male sex (OR 0.52; 95%CI, 0.30 to 0.82) and OPUS treatment (OR 1.83; 95%CI, 1.06 to 3.15) were significantly associated with outcome at the 2-year follow-up. In the domain of hospitalization, better Table 3 
Proportion of interviewed patients (n = 369) meeting good outcome variables and the Pearson's product-moment correlation coefficients at 2-year follow-up
Discussion
Studies of first-episode samples have the advantage of not only potentially comparable cohorts that are not yet institutionalized and chronic but also observing processes that are close to the early development of the disease. However, even for first-episode outcome studies, heterogeneous outcome has been reported, with a relatively small proportion experiencing significant improvement (20% to 50%). 32 Much of the heterogeneity described in the course and outcome of first-episode SSD may, however, be attributed to their differing length of follow-up and lack of agreement on outcome criteria such as remission and recovery and scales used to measure outcome. 30, 34 In this study of first-episode patients diagnosed within SSD, we examined several predictors chosen on the basis of their known relevance concerning good outcomes. We measured outcome on various criteria within the clinical, social and vocational, and hospitalization domains, because outcome for schizophrenia and schizophrenia-like disorders are considered heterogeneous and multidimensional. 35, 36 Partially independent predictors may potentially influence heterogeneous outcome domains differently.
Although the results largely confirmed previous findings, we think our results are important owing to our large number of first-episode patients, which is associated with high statistical power and is, to a large extent, epidemiologically representative. To our knowledge, this is the largest prospective study of this kind investigating predictors of outcome in first-episode psychosis. In addition, we have high-quality data based on internationally well-known rating scales and a relatively high proportion of face-to-face interviews at follow-up.
Symptoms
Two-thirds of the patients had mild or less psychotic symptoms, and about one-half of the interviewed patients had no or mild negative symptoms at the 2-year follow-up. About one-third of the patients were in remission. This is largely in accordance with many other studies.
DUP did influence the level of psychotic and negative symptoms and was associated with being fully recovered. The association remained significant for level of psychotic symptoms even after adjustment for potential confounders, and this is in line with other studies finding that DUP correlated significantly with symptom outcome. 2, 6, 37 Premorbid functioning significantly predicted negative symptom outcome. The association between poor premorbid social adaptation and more severe negative symptoms is in accordance with other studies suggesting a developmental continuity from premorbid cognitive and social impairment to negative symptoms.
Similar to Malla et al, 38 we also found that symptom outcome was strongly influenced by adherence to medication.
Substance abuse at baseline was found to be a powerful predictor of no good outcome in the univariate analyses, but in the multivariate analyses this association became insignificant for all outcome variables except psychotic symptoms. Patients with substance abuse were significantly more likely to drop out of our study and this may partly explain that we did not observe a stronger association between substance abuse and outcome as other studies have found that substance abuse worsens the course of schizophrenia and schizophrenia-like disorders and that recent onset schizophrenia patients with substance abuse have poorer outcome. 39 Further, we know from previous analyses that some of the patients actually stopped abusing substances during the follow-up period 18 and this might have weakened the association further.
Similar to our previous analyses, 18, 40 OPUS treatment had a convincing effect on negative symptoms. OPUS treatment increased the chances of having no or only mild negative symptoms by 75% and the effect persisted after controlling for adherence to medication. In contrast to previous analyses, our analysis of the effect of OPUS treatment did not show any effect on psychotic symptoms. This is probably because the outcome measure was dichotomized.
Psychosocial Functioning
Less than one-half of the patients were engaged in education or work during the study. In their review of schizophrenia and employment, Marwaha and Johnson 41 found that studies of first-episode schizophrenia indicated that a majority of the people using services for the first time were already unemployed. A substantial decrease in employment rates from baseline to follow-up is also described in their studies. In our study, work and education rates remained the same from entry to follow-up. This could be a result of attrition as significantly more patients with only secondary school dropped out of the study, indicating that the employment rates are perhaps even lower than observed among participants.
Recovery
In our study, we found that for patients with schizophrenia, 26% were symptomatically remitted and 15% were fully recovered. It is promising that already 2 years after the first episode of illness, one-third of the patients can be considered symptomatically or functionally remitted. However, a main limitation of the study is the proportion of patients who dropped out, and as dropping out was apparently to some degree associated with poor outcome, it is likely that the actual percentages of patients in remission or recovery are lower.
We set the criteria for good outcomes in accordance with the recommendations of Andreasen et al. 30 As this is a 2-year follow-up of a first onset sample, it has not been possible to fulfill the criteria for full recovery of at least 2 years' duration of sustained symptomatic and normal functioning.
The proportion of patients meeting criteria for full recovery resembles those found by Robinson and colleagues 42 who used almost the same criteria in their study of 118 subjects with first episode of schizophrenia or schizoaffective disorders. At a 5-year follow-up, 47% achieved symptom remission and 14% met full recovery criteria of at least 2 years' duration. Although the recovery rates cannot easily be compared across studies, some patients with schizophrenia do apparently recover.
Conclusion
The results seem to indicate that premorbid functioning at the debut of psychosis is an important aspect of the disease process and continuity of disease development is further supported by the baseline values of the included rating scales, which were found to strongly predict outcome at the 2-year follow-up. Among potentially malleable predictors of recovery in this sample DUP, substance abuse, adherence to medication, and OPUS treatment were all associated to recovery in univariate analyses. Focusing on these factors early in the course of treatment may be important to improve short-term outcome. Méthode : Nous avons mené un suivi de 2 ans auprès d'une cohorte de patients (n = 547) à leur premier épisode du TSS. Nous avons évalué les patients selon les variables démographiques, le diagnostic, la durée de la psychose non traitée (DPNT), le fonctionnement pré-morbide, les symptômes psychotiques et négatifs, l'abus de substances, l'observance de la médication, et l'utilisation des services. Les risques relatifs étaient calculés par des analyses de régression logistique.
Funding and Support
Résultats : Un total de 369 patients (67 %) ont participé à l'entrevue de suivi. Après 2 ans, 36 % étaient en rémission et 17 % étaient considérés complètement rétablis. Le rétablissement complet était associé avec une DPNT plus courte, une meilleure adaptation pré-morbide, des symptômes négatifs moins nombreux au départ, l'absence d'abus de substances au départ, et l'observance de la médication et du traitement OPUS.
Conclusions :
Plusieurs facteurs prédicteurs ont été identifiés, et l'accent devrait être mis sur les prédicteurs de résultat potentiellement malléables, par exemple, réduire la DPNT et porter une attention particulière aux patients qui ne sont pas susceptibles d'atteindre un bon résultat, comme par exemple les patients ayant un problème d'abus de substances et une mauvais adaptation pré-morbide.
